🩸 WaVE Study Alert!
In patients with acute CAT & weight >90kg, weight-based dalteparin (200 IU/kg) appears safe & effective.
🔹 Anti-Xa levels aligned with non-obese patients
🔹 Higher levels seen in those with bleeding

Important data to guide dosing CAT & obesity.
📍Presented by Dr. Wang at #ISTH2025

🚨 SPECTACULAR RCT at #ISTH2025!

Although non-inferiority to CTPA wasn’t shown, a negative SPECT V/Q scan led to low 3-month VTE risk—
✅ Supporting the safety of ruling out PE with a SPECT-based algorithm
📸 PE diagnosis rates matched other validated strategies

SPECTacular findings indeed! 🫁💥

This is what we were waiting for. A direct comparison between apixaban and rivaroxaban for the treatment of acute VTE. Apixaban reduces bleeding risk in the first 3 months by >50%!

Practice changing investigator-initiated RCT.

#ISTH2025

In non-critically ill COVID-19 patients, therapeutic-dose anticoagulation reduced the odds of organ support, thrombosis, or death at 28 days.

🔴 Bleeding risk increased, but absolute risk stayed low.
No high-credibility effect modifiers identified.
👏 Nice work @TritschlerMD
#ISTH2025 #COVID19 #VTE

WEBINAR: The NLRP3 Inflammasome and Interleukin-1 in Thromboinflammation and #VTE

Join us for the next edition of our National Thrombosis Seminar series on February 4th at 11 am ET !

Featuring: Nicola Potere, MD

Register: buff.ly/4g04UHl

#Thrombosis #Research